• 四川大學華西醫(yī)院教育部人類疾病生物治療重點實驗室與腫瘤中心（成都610041）;

引用本文： 魏于全,吳揚. 乳腺癌生物治療進展. 中國普外基礎與臨床雜志, 2004, 11(1): 3-5. doi: 復制

1. Sakorafas GH, Krespis E, Pavlakis G. Risk estimation for breast cancer development; a clinical perspective [J]. Surg Oncol， 2002; 10(4)∶183.
2. 吳揚， 楊莉， 魏于全. 乳腺癌相關基因的分子遺傳學研究進展 [J]. 中華醫(yī)學遺傳學雜志， 2002； 19(2)∶152.
3. Sorokin P. New agents and future directions in biotherapy [J]. Clin J Oncol Nurs， 2002; 6(1)∶19.
4. Knutson KL, Bishop MR, Schiffman K, et al. Immunotherapy for breast cancer [J]. Cancer Chemother Biol Response Modif, 2002; 20∶351.
5. Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment [J]. Expert Rev Anticancer Ther, 2003; 3(3)∶403.
6. Menard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer [J]. Oncology, 2001; 61 Suppl 2∶67.
7. Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer [J]. Clin Ther, 1999; 21(2)∶309.
8. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer [J]. Semin Oncol, 2002; 29(3 Suppl 11)∶38.
9. Christodoulou C, Klouvas G, Pateli A, et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer [J]. Anticancer Res, 2003; 23(1B)∶737.
10. Avigan D. Fusions of breast cancer and dendritic cells as a novel cancer vaccine [J]. Clin Breast Cancer, 2003; 3 Suppl 4∶S158.
11. Pulaski BA, OstrandRosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cellbased tumor vaccines [J]. Cancer Res, 1998; 58(7)∶1486.
12. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirusmediated gene transfer [J]. Curr Gene Ther, 2001; 1(1)∶101.
13. Dummer R, Bergh J, Karlsson Y, et al. Biological activity and safety of adenoviral vectorexpressed wildtype p53 after intratumoral injection in melanoma and breast cancer patients with p53overexpressing tumors [J]. Cancer Gene Ther, 2000; 7(7)∶1069.
14. Bougeret C, VironeOddos A, Adeline E, et al. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wildtype p53 in growth inhibition of human tumors overexpressing MDM2 [J]. Cancer Gene Ther, 2000; 7(5)∶789.
15. Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer [J]. Gan To Kagaku Ryoho, 2003; 30(4)∶468.
16. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without highdose chemotherapy and autologous stemcell transplantation in highrisk breast cancer [J]. N Engl J Med, 2003; 349(1)∶17.
17. Harris AL, Zhang H, Moghaddam A, et al. Breast cancer angiogenesisnew approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting [J]. Breast Cancer Res Treat, 1996; 38(1)∶97.
18. Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy [J]. Curr Drug Targets Immune Endocr Metabol Disord, 2001; 1(3)∶241.
  1. 1. Sakorafas GH, Krespis E, Pavlakis G. Risk estimation for breast cancer development; a clinical perspective [J]. Surg Oncol， 2002; 10(4)∶183.
  2. 2. 吳揚， 楊莉， 魏于全. 乳腺癌相關基因的分子遺傳學研究進展 [J]. 中華醫(yī)學遺傳學雜志， 2002； 19(2)∶152.
  3. 3. Sorokin P. New agents and future directions in biotherapy [J]. Clin J Oncol Nurs， 2002; 6(1)∶19.
  4. 4. Knutson KL, Bishop MR, Schiffman K, et al. Immunotherapy for breast cancer [J]. Cancer Chemother Biol Response Modif, 2002; 20∶351.
  5. 5. Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment [J]. Expert Rev Anticancer Ther, 2003; 3(3)∶403.
  6. 6. Menard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer [J]. Oncology, 2001; 61 Suppl 2∶67.
  7. 7. Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer [J]. Clin Ther, 1999; 21(2)∶309.
  8. 8. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer [J]. Semin Oncol, 2002; 29(3 Suppl 11)∶38.
  9. 9. Christodoulou C, Klouvas G, Pateli A, et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer [J]. Anticancer Res, 2003; 23(1B)∶737.
  10. 10. Avigan D. Fusions of breast cancer and dendritic cells as a novel cancer vaccine [J]. Clin Breast Cancer, 2003; 3 Suppl 4∶S158.
  11. 11. Pulaski BA, OstrandRosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cellbased tumor vaccines [J]. Cancer Res, 1998; 58(7)∶1486.
  12. 12. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirusmediated gene transfer [J]. Curr Gene Ther, 2001; 1(1)∶101.
  13. 13. Dummer R, Bergh J, Karlsson Y, et al. Biological activity and safety of adenoviral vectorexpressed wildtype p53 after intratumoral injection in melanoma and breast cancer patients with p53overexpressing tumors [J]. Cancer Gene Ther, 2000; 7(7)∶1069.
  14. 14. Bougeret C, VironeOddos A, Adeline E, et al. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wildtype p53 in growth inhibition of human tumors overexpressing MDM2 [J]. Cancer Gene Ther, 2000; 7(5)∶789.
  15. 15. Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer [J]. Gan To Kagaku Ryoho, 2003; 30(4)∶468.
  16. 16. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without highdose chemotherapy and autologous stemcell transplantation in highrisk breast cancer [J]. N Engl J Med, 2003; 349(1)∶17.
  17. 17. Harris AL, Zhang H, Moghaddam A, et al. Breast cancer angiogenesisnew approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting [J]. Breast Cancer Res Treat, 1996; 38(1)∶97.
  18. 18. Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy [J]. Curr Drug Targets Immune Endocr Metabol Disord, 2001; 1(3)∶241.